June 2017
Volume 58, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2017
Modulation of electrical activity in the retina of the rd10 mouse model using neuroprotective drugs
Author Affiliations & Notes
  • Kim Schaffrath
    Department of Ophthalmology, University Hospital RWTH Aachen, Aachen, Germany
  • Sabine Diarra
    Department of Ophthalmology, University Hospital RWTH Aachen, Aachen, Germany
  • Claudia Werner
    Department of Ophthalmology, University Hospital RWTH Aachen, Aachen, Germany
  • Anna-Marina van der Meer
    Department of Ophthalmology, University Hospital RWTH Aachen, Aachen, Germany
  • Inga Schulte-Noelke
    Department of Ophthalmology, University Hospital RWTH Aachen, Aachen, Germany
  • Frank Muller
    Institute of Complex Systems, Cellular Biophysics, ICS-4, Forschungszentrum Juelich, Juelich, Germany
  • Sandra Johnen
    Department of Ophthalmology, University Hospital RWTH Aachen, Aachen, Germany
  • Peter Walter
    Department of Ophthalmology, University Hospital RWTH Aachen, Aachen, Germany
  • Footnotes
    Commercial Relationships   Kim Schaffrath, None; Sabine Diarra, None; Claudia Werner, None; Anna-Marina van der Meer, None; Inga Schulte-Noelke, None; Frank Muller, None; Sandra Johnen, None; Peter Walter, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2017, Vol.58, 242. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Kim Schaffrath, Sabine Diarra, Claudia Werner, Anna-Marina van der Meer, Inga Schulte-Noelke, Frank Muller, Sandra Johnen, Peter Walter; Modulation of electrical activity in the retina of the rd10 mouse model using neuroprotective drugs. Invest. Ophthalmol. Vis. Sci. 2017;58(8):242.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : The rd10 mouse is a commonly used animal model of retinal degenerative diseases, e.g., retinitis pigmentosa. The rd10 retina shows spontaneous electrical activity with oscillations between 3 and 7 Hz. In comparison to the wildtype retina, ganglion cells in the degenerated rd10 retina are electrically less excitable. We hypothesized that neuroprotective drugs (e.g., taurine, brain-derived neurotrophic factor, pigment epithelium-derived factor) could modulate the electrical activity of the surviving retinal ganglion cells. We want to analyze if the drugs can reduce or abolish the spontaneous rhythmic activity and investigate if they can improve the retinal responses to different stimulation patterns.

Methods : Retinas from rd10 mice aged P28 to P30 were isolated and placed on multielectrode arrays. Perfusion experiments were performed using the following standardized protocol: retinas were perfused (1) with ames’ medium, (2) with ames’ medium plus the neuroprotective drug and (3) with ames’ medium in order to analyze the reversibility of the drugs’ effect. Every step lasted for 30 minutes. To confirm the drugs’ effect, step 2 und 3 were repeated. During perfusion, multielectrode recordings were performed to analyze the spontaneous electrical activity as well as the activity induced by electrical stimulation with currents ranging from 20 to 80 µA. For statistical analysis, two-tailed student’s t-test and one-way ANOVA analysis were used.

Results : The spontaneous oscillations of rd10 retinas showed a frequency of 7 Hz. The frequency could be shifted to 12 Hz (p<0,0001) by perfusion with 1 mM taurine. This effect was reversible and no significant difference between the first and second perfusion with taurine was observed. Additionally, a tendency that retinas perfused with taurine were slightly more excitable became apparent; however, this tendency is so far without any statistical significance.

Conclusions : Treatment with taurine could modulate the spontaneous oscillations and the excitability in degenerated rd10 retinas. The results are a first step towards the combined use of microelectrode array-based stimulation together with neuroprotective drugs to improve electrical activity in retinas affected by degenerative diseases.

This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×